Use este identificador para citar ou linkar para este item:
http://www.repositorio.ufop.br/jspui/handle/123456789/14112
Título: | Fixed dose drug combinations - are they pharmacoeconomically sound? : findings and implications especially for lower- and middle-income countries. |
Autor(es): | Godman, Brian McCabe, Holly Leong, Trudy D. Mueller, Debjani Martin, Antony P. Hoxha, Iris Mwita, Julius C. Rwegerera, Godfrey Mutashambara Massele, Amos Costa, Juliana de Oliveira Nascimento, Renata Cristina Rezende Macedo do Lemos, Livia Lovato Pires de Tachkov, Konstantin Milushewa, Petya Patrick, Okwen Niba, Loveline Lum Laius, Ott Sefah, Israel Abdulsalim, Suhaj Soleymani, Fatemeh Guantai, Anastasia N. Achieng, Loice Oluka, Margaret Jakupi, Arianit Logvissee, Konstantīns Hassali, Mohamed Azmi Kibuule, Dan Kalemeera, Francis Mubita, Mwangana Fadare, Joseph Ogunleye, Olayinka O. Saleem, Zikria Hussain, Shazhad Bochenek, Tomasz Mardare, Ileana Alrasheedy, Alian A. Furst, Jurij Tomek, Dominik Pekovic, Vanda Markovic Rampamba, Enos M. Alfadl, Abubakr Amuuu, Adefolarin A. Matsebula, Zinhle Phuong, Thuy Nguyen Thi Thanh, Binh Nguyen Kalungia, Aubrey Chichonyi Zaranyika, Trust Masuka, Nyasha Olaru, Ioana D. Waleccc, Janney Hill, Ruaraidh Kurdi, Amanj Timoney, Angela Campbell, Stephen Meyer, Johanna C. |
Palavras-chave: | Adherence Medicines Non communicable diseases Infectious diseases |
Data do documento: | 2020 |
Referência: | GODMAN, B. et al. Fixed dose drug combinations - are they pharmacoeconomically sound?: findings and implications especially for lower- and middle-income countries. Expert Review of Pharmacoeconomics & Outcomes Research, v. 20, n. 1, 2020. Disponível em: <https://www.tandfonline.com/doi/full/10.1080/14737167.2020.1734456>. Acesso em: 10 jun. 2021. |
Resumo: | Introduction: There are positive aspects regarding the prescribing of fixed dose combinations (FDCs) versus prescribing the medicines separately. However, these have to be balanced against concerns including increased costs and their irrationality in some cases. Consequently, there is a need to review their value among lower- and middle-income countries (LMICs) which have the greatest prevalence of both infectious and noninfectious diseases and issues of affordability. Areas covered: Review of potential advantages, disadvantages, cost-effectiveness, and availability of FDCs in high priority disease areas in LMICs and possible initiatives to enhance the prescribing of valued FDCs and limit their use where there are concerns with their value. Expert commentary: FDCs are valued across LMICs. Advantages include potentially improved response rates, reduced adverse reactions, increased adherence rates, and reduced costs. Concerns include increased chances of drug:drug interactions, reduced effectiveness, potential for imprecise diagnoses and higher unjustified prices. Overall certain FDCs including those for malaria, tuberculosis, and hypertension are valued and listed in the country’s essential medicine lists, with initiatives needed to enhance their prescribing where currently low prescribing rates. Proposed initiatives include robust clinical and economic data to address the current paucity of pharmacoeconomic data. Irrational FDCs persists in some countries which are being addressed. |
URI: | http://www.repositorio.ufop.br/jspui/handle/123456789/14112 |
Link para o artigo: | https://www.tandfonline.com/doi/full/10.1080/14737167.2020.1734456 |
DOI: | https://doi.org/10.1080/14737167.2020.1734456 |
ISSN: | 1744-8379 |
Aparece nas coleções: | DEFAR - Artigos publicados em periódicos |
Arquivos associados a este item:
Arquivo | Descrição | Tamanho | Formato | |
---|---|---|---|---|
ARTIGO_FixedDoseDrug.pdf Restricted Access | 5,62 MB | Adobe PDF | Visualizar/Abrir |
Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.